Samsung Biologics Co.,

Samsung Biologics (207940 KS): Well-Positioned to Leap Forward Without Biogen Deal

Equity Bottom-Up
184 Views, 20 Jan 2022 23:09
EXECUTIVE SUMMARY
  • Samsung Biologics Co., (207940 KS) has denied its acquisition talk with Biogen Inc (BIIB US). With its current controversies, Biogen does not seem to be an attractive bet.
  • The company is poised for strong growth in 2022, driven by its massive capacity expansion plans and portfolio diversification toward high-growth areas like cell & gene therapies and mRNA business.  
  • With an increasing order backlog resulting from consistent contract win and expanding customer base, Samsung Biologics has strong revenue visibility.
detail (6-minute read)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
logo
Logo
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare compa... 

Zoom:
NaN%
x